Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
3.0
Journals
Diagnostics
Special Issues
Research Progress in NephroOncology
share announcement

Research Progress in NephroOncology

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: closed (31 May 2021) | Viewed by 29537

Special Issue Editors

Dr. Dil Sahali

E-Mail Website
Guest Editor
Mondor Institute for Biomedical Research, Paris, France
Dr. Hassan Izzedine

E-Mail
Guest Editor
Department of nephrology, Peuplier private hospital, Ramsay GDS, Paris, France
Interests: nephrology; onco-nephrology; drug toxicity
Dr. Vincent Audard

E-Mail Website
Co-Guest Editor
Assistance Publique – Hôpitaux de Paris | AP-HP • Nephrology and Renal Transplantation, Paris, France
Interests: focal segmental glomerulosclerosis; chronic kidney failure; acute kidney injury; nephrotic syndrome; clinical nephrology; renal disease
Dr. Carole Henique

E-Mail Website
Co-Guest Editor
Université Paris-Est Créteil Val de Marne - Université Paris 12 | UPEC · Team 21, Paris, France
Interests: molecular cell biology
Prof. Dr. Mario Ollero

E-Mail Website
Co-Guest Editor
UPEC, Institut Mondor de Recherche Biomédicale (IMRB), Université Paris-Est Créteil Val de Marne—Université Paris 12, U955 Créteil, France
Interests: lipid signaling; membrane microdomains; protein-lipid interactions
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Kidney disorders associated with either cancer or anti-cancer therapies represent a growing challenge in human pathology. While understanding the underlying mechanisms becomes essential, it represents a real challenge. Hence NephroOncology has emerged as a new field covering the need for mechanistic knowledge of the molecular mechanisms at the cellular and tissular levels. The current special issue intends to contribute to the development of this domain and provide leverage for further research. Potential readers in medicine, biology and connected disciplines should have access to the state of the art information and to the most recent advances in associated diagnostics, pathogenesis, and therapeutic strategies at the crossroads of cancer and nephrology.

Authors are invited to submit original research and review articles. Clinical cases and studies are also welcome. Topics include, but are not limited to:

  • Angiogenesis, and therapeutic targets in cancer.
  • Molecular bases of immunotherapy in cancer
  • Renal complications associated with cancer including hemopathies
  • Renal complications associated with cancer therapy: chimiotherapy, targeted therapies, immunotherapy
  • Cancer patient care in the case of chronic renal insufficiency.
  • Cancer and transplantation.

Dr. Dil Sahali
Guest Editor
Dr. Vincent Audard
Dr. Carole Henique
Dr. Mario Ollero
Co-Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Cancer (including malignant hemopathies)
  • Translational research
  • Kidney diseases
  • Targeted Therapy: chemotherapy
  • Immunotherapy
  • Biotherapy
  • Transplantation

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (5 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

10 pages, 1011 KiB  
Article
Comparison of Robot-Assisted Laparoscopic Partial Nephrectomy with Laparoscopic Cryoablation in the Treatment of Localised Renal Tumours: A Propensity Score-Matched Comparison of Long-Term Outcomes
by Hui-Ying Liu, Chih-Hsiung Kang, Hung-Jen Wang, Chien-Hsu Chen, Hao-Lun Luo, Yen-Ta Chen, Yuan-Tso Cheng and Po-Hui Chiang
Diagnostics 2021, 11(5), 759; https://doi.org/10.3390/diagnostics11050759 - 23 Apr 2021
Cited by 7 | Viewed by 2129
Abstract
Preserving renal function and controlling oncological outcomes are pertinent when managing renal neoplasms. Cryoablation is the recommended treatment only for clinical T1a stage renal tumour. Here, we compared the outcomes of robot-assisted laparoscopic partial nephrectomy (RaPN) and laparoscopic cryoablation (LCA) in the treatment [...] Read more.
Preserving renal function and controlling oncological outcomes are pertinent when managing renal neoplasms. Cryoablation is the recommended treatment only for clinical T1a stage renal tumour. Here, we compared the outcomes of robot-assisted laparoscopic partial nephrectomy (RaPN) and laparoscopic cryoablation (LCA) in the treatment of patients with localised T1-T2 renal tumours. Overall, 86 patients who received RaPN and 78 patients underwent LCA were included in this study. The intraoperative, postoperative, and oncological outcomes in the LCA group were non-inferior to the RaPN group. Moreover, LCA demonstrated shorter operative time (267.45 ± 104.53 min vs. 138.56 ± 45.28 min, p < 0.001), lower blood loss (300.56 ± 360.73 mL vs. 30.73 ± 50.31 mL, p < 0.001), and slight renal function deterioration because of the reduced invasiveness, without compromising on the oncological outcomes. Full article
(This article belongs to the Special Issue Research Progress in NephroOncology)
►▼ Show Figures

Figure 1

Review

Jump to: Research

15 pages, 3022 KiB  
Review
Renal Complications Related to Checkpoint Inhibitors: Diagnostic and Therapeutic Strategies
by Julie Belliere, Julien Mazieres, Nicolas Meyer, Leila Chebane and Fabien Despas
Diagnostics 2021, 11(7), 1187; https://doi.org/10.3390/diagnostics11071187 - 30 Jun 2021
Cited by 13 | Viewed by 5329
Abstract
Immune checkpoint inhibitors (ICI) targeting CTLA-4 and the PD-1/PD-L1 axis have unprecedentedly improved global prognosis in several types of cancers. However, they are associated with the occurrence of immune-related adverse events. Despite their low incidence, renal complications can interfere with the oncologic strategy. [...] Read more.
Immune checkpoint inhibitors (ICI) targeting CTLA-4 and the PD-1/PD-L1 axis have unprecedentedly improved global prognosis in several types of cancers. However, they are associated with the occurrence of immune-related adverse events. Despite their low incidence, renal complications can interfere with the oncologic strategy. The breaking of peripheral tolerance and the emergence of auto- or drug-reactive T-cells are the main pathophysiological hypotheses to explain renal complications after ICI exposure. ICIs can induce a large spectrum of renal symptoms with variable severity (from isolated electrolyte disorders to dialysis-dependent acute kidney injury (AKI)) and presentation (acute tubule-interstitial nephritis in >90% of cases and a minority of glomerular diseases). In this review, the current trends in diagnosis and treatment strategies are summarized. The diagnosis of ICI-related renal complications requires special steps to avoid confounding factors, identify known risk factors (lower baseline estimated glomerular filtration rate, proton pump inhibitor use, and combination ICI therapy), and prove ICI causality, even after long-term exposure (weeks to months). A kidney biopsy should be performed as soon as possible. The treatment strategies rely on ICI discontinuation as well as co-medications, corticosteroids for 2 months, and tailored immunosuppressive drugs when renal response is not achieved. Full article
(This article belongs to the Special Issue Research Progress in NephroOncology)
►▼ Show Figures

Figure 1

16 pages, 2632 KiB  
Review
Renal Diseases Associated with Hematologic Malignancies and Thymoma in the Absence of Renal Monoclonal Immunoglobulin Deposits
by Antoine Morel, Marie-Sophie Meuleman, Anissa Moktefi and Vincent Audard
Diagnostics 2021, 11(4), 710; https://doi.org/10.3390/diagnostics11040710 - 15 Apr 2021
Cited by 9 | Viewed by 8148
Abstract
In addition to kidney diseases characterized by the precipitation and deposition of overproduced monoclonal immunoglobulin and kidney damage due to chemotherapy agents, a broad spectrum of renal lesions may be found in patients with hematologic malignancies. Glomerular diseases, in the form of paraneoplastic [...] Read more.
In addition to kidney diseases characterized by the precipitation and deposition of overproduced monoclonal immunoglobulin and kidney damage due to chemotherapy agents, a broad spectrum of renal lesions may be found in patients with hematologic malignancies. Glomerular diseases, in the form of paraneoplastic glomerulopathies and acute kidney injury with various degrees of proteinuria due to specific lymphomatous interstitial and/or glomerular infiltration, are two major renal complications observed in the lymphoid disorder setting. However, other hematologic neoplasms, including chronic lymphocytic leukemia, thymoma, myeloproliferative disorders, Castleman disease and hemophagocytic syndrome, have also been associated with the development of kidney lesions. These renal disorders require prompt recognition by the clinician, due to the need to implement specific treatment, depending on the chemotherapy regimen, to decrease the risk of subsequent chronic kidney disease. In the context of renal disease related to hematologic malignancies, renal biopsy remains crucial for accurate pathological diagnosis, with the aim of optimizing medical care for these patients. In this review, we provide an update on the epidemiology, clinical presentation, pathophysiological processes and diagnostic strategy for kidney diseases associated with hematologic malignancies outside the spectrum of monoclonal gammopathy of renal significance. Full article
(This article belongs to the Special Issue Research Progress in NephroOncology)
►▼ Show Figures

Figure 1

15 pages, 2932 KiB  
Review
Acute Kidney Injury in the Patient with Cancer
by Alejandro Meraz-Munoz, Amit Langote, Kenar D. Jhaveri, Hassane Izzedine and Prakash Gudsoorkar
Diagnostics 2021, 11(4), 611; https://doi.org/10.3390/diagnostics11040611 - 29 Mar 2021
Cited by 19 | Viewed by 8743
Abstract
Over the last three decades, advancements in the diagnosis, treatment, and supportive care of patients with cancer have significantly improved their overall survival. However, these advancements have also led to a higher rate of cancer-related complications. Acute kidney injury (AKI) and chronic kidney [...] Read more.
Over the last three decades, advancements in the diagnosis, treatment, and supportive care of patients with cancer have significantly improved their overall survival. However, these advancements have also led to a higher rate of cancer-related complications. Acute kidney injury (AKI) and chronic kidney disease (CKD) are highly prevalent in patients with cancer, and they are associated with an increased risk of all-cause mortality. This bidirectional interplay between cancer and kidney, termed “the kidney–cancer connection” has become a very active area of research. This review aims to provide an overview of some of the most common causes of AKI in patients with cancer. Cancer therapy-associated AKI is beyond the scope of this review and will be discussed separately. Full article
(This article belongs to the Special Issue Research Progress in NephroOncology)
►▼ Show Figures

Figure 1

13 pages, 2935 KiB  
Review
Randall-Type Monoclonal Immunoglobulin Deposition Disease: New Insights into the Pathogenesis, Diagnosis and Management
by Camille Cohen, Florent Joly, Audrey Sibille, Vincent Javaugue, Estelle Desport, Jean-Michel Goujon, Guy Touchard, Jean-Paul Fermand, Christophe Sirac and Frank Bridoux
Diagnostics 2021, 11(3), 420; https://doi.org/10.3390/diagnostics11030420 - 2 Mar 2021
Cited by 9 | Viewed by 3882
Abstract
Randall-type monoclonal immunoglobulin deposition disease (MIDD) is a rare disease that belongs to the spectrum of monoclonal gammopathy of renal significance (MGRS). Renal involvement is prominent in MIDD, but extra-renal manifestations can be present and may affect global prognosis. Recent data highlighted the [...] Read more.
Randall-type monoclonal immunoglobulin deposition disease (MIDD) is a rare disease that belongs to the spectrum of monoclonal gammopathy of renal significance (MGRS). Renal involvement is prominent in MIDD, but extra-renal manifestations can be present and may affect global prognosis. Recent data highlighted the central role of molecular characteristics of nephrotoxic monoclonal immunoglobulins in the pathophysiology of MIDD, and the importance of serum free light chain monitoring in the diagnosis and follow-up disease. Clone-targeted therapy is required to improve the overall and renal survival, and the achievement of a rapid and deep hematological response is the goal of therapy. This review will focus on the recent progress in the pathogenesis and management of this rare disease. Full article
(This article belongs to the Special Issue Research Progress in NephroOncology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-5
Back to TopTop